- Home
- RARE vs LEA Comparison
RARE vs LEA Comparison
Compare RARE & LEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- LEA
- Stock Information
- Founded
- RARE 2010
- LEA 1917
- Country
- RARE United States
- LEA United States
- Employees
- RARE N/A
- LEA N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- LEA Auto Parts:O.E.M.
- Sector
- RARE Health Care
- LEA Consumer Discretionary
- Exchange
- RARE Nasdaq
- LEA Nasdaq
- Market Cap
- RARE 5.2B
- LEA 5.4B
- IPO Year
- RARE 2014
- LEA N/A
- Fundamental
- Price
- RARE $43.98
- LEA $94.81
- Analyst Decision
- RARE Strong Buy
- LEA Buy
- Analyst Count
- RARE 14
- LEA 13
- Target Price
- RARE $88.43
- LEA $142.00
- AVG Volume (30 Days)
- RARE 717.6K
- LEA 896.5K
- Earning Date
- RARE 02-13-2025
- LEA 02-04-2025
- Dividend Yield
- RARE N/A
- LEA 3.25%
- EPS Growth
- RARE N/A
- LEA 0.30
- EPS
- RARE N/A
- LEA 9.50
- Revenue
- RARE $522,745,000.00
- LEA $23,432,600,000.00
- Revenue This Year
- RARE $27.36
- LEA N/A
- Revenue Next Year
- RARE $18.61
- LEA $1.55
- P/E Ratio
- RARE N/A
- LEA $9.98
- Revenue Growth
- RARE 27.44
- LEA 1.90
- 52 Week Low
- RARE $37.02
- LEA $91.70
- 52 Week High
- RARE $60.37
- LEA $147.11
- Technical
- Relative Strength Index (RSI)
- RARE 33.50
- LEA 41.53
- Support Level
- RARE $41.45
- LEA $91.70
- Resistance Level
- RARE $50.00
- LEA $97.35
- Average True Range (ATR)
- RARE 1.83
- LEA 2.66
- MACD
- RARE -0.31
- LEA -0.64
- Stochastic Oscillator
- RARE 26.55
- LEA 23.60
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About LEA Lear Corporation
Lear designs, develops, and manufactures automotive seating and electrical systems and components. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems, high-voltage power distribution systems, domain controllers, telematics control units, gateway modules, vehicle positioning for automated and autonomous driving, embedded control software, cloud and mobile device software and services, and cybersecurity. Lear's largest customer and regional market is GM and North America at 20% and 44% of 2022 revenue, respectively.